Oral versus Intravenous Opioid Dosing for the Initial Treatment of Acute Musculoskeletal Pain in the Emergency Department
|
|
- June Emma Cook
- 5 years ago
- Views:
Transcription
1 CLINICAL INVESTIGATION Oral versus Intravenous Opioid Dosing for the Initial Treatment of Acute Musculoskeletal Pain in the Emergency Department James R. Miner, MD, Johanna Moore, MD, Richard O. Gray, MD, Lisa Skinner, MD, Michelle H. Biros, MS, MD Abstract Objectives: The objective was to compare the time to medication administration, the side effects, and the analgesic effect at sequential time points after medication administration of an oral treatment strategy using oxycodone solution with an intravenous (IV) treatment strategy using morphine sulfate for the initial treatment of musculoskeletal pain in emergency department (ED) patients. Methods: This was a prospective randomized clinical trial of patients >6 years old who were going to receive IV morphine sulfate for the treatment of musculoskeletal pain but did not yet have an IV. Consenting patients were randomized to have the treating physician order either 0.1 mg kg morphine sulfate IV or mg kg oxycodone orally in a 5 mg 5 ml suspension as their initial treatment for pain. The time from the placement of the order to the administration of the medication was recorded. Pain was measured using a 100-mm visual analog scale (VAS) and recorded at 0, 10, 20, 30 and 40 minutes after drug administration. Results: A total of 405 eligible patients were identified during the study period; 328 (81.0%) patients consented to be in the study. A total of 158 patients were randomized to the IV morphine sulfate treatment group, and 162 were randomized to the oral oxycodone treatment group. Of the patients who were randomized to IV therapy, 34 were withdrawn from the study prior to drug administration; leaving 125 patients in the IV group for analysis. Of the patients who randomized to oral therapy, 22 were withdrawn from the study prior to drug administration, leaving 140 patients for analysis. No serious adverse events were detected. There was a 12-minute difference between the median time of the order and the administration of oral oxycodone (8.5 minutes) and IV morphine (20.5 minutes). The mean percent change in VAS score was larger for patients in the IV therapy group than those in the oral therapy group at 10 and 20 minutes. At 30 and 40 minutes, the authors could no longer detect a difference. The satisfaction scale score was higher after treatment for the morphine group (median = 4; interquartile range [IQR] = 4 to 5) than for the oxycodone group (median = 4; IQR = 2 to 5; p = 0.008). Conclusions: The oral loading strategy was associated with delayed onset of analgesia and decreased patient satisfaction, but a shorter time to administration. The oral loading strategy using an oxycodone solution provided similar pain relief to the IV strategy using morphine 30 minutes after administration of the drug. Oral mg kg oxycodone represents a feasible alternative to 0.1 mg kg IV morphine in the treatment of severe acute musculoskeletal pain when difficult or delayed IV placement greater than 30 minutes presents a barrier to treatment. ACADEMIC EMERGENCY MEDICINE 2008; 15: ª 2008 by the Society for Academic Emergency Medicine Keywords: pain, treatment, oxycodone, morphine, emergency department, emergency medicine Both adult and pediatric trauma patients often receive inadequate analgesia in the emergency department (ED). 1 6 There are a variety of barriers to pain treatment, many related to the assessment of pain and many related to treatment practices. Acute pain is, however, essentially an easy thing to treat. There are a From the Department of Emergency Medicine, Hennepin County Medical Center (JRM, JM, ROG, LS, MHB), Minneapolis, MN. Received June 4, 2008; revision received July 28, 2008; accepted August 1, Presented in part at the Society for Academic Emergency Medicine (SAEM) Annual Meeting, San Francisco, CA, May 2006 (adult data), and at the American College of Emergency Physicians (ACEP) Research Forum, New Orleans, LA, October 2006 (pediatric data). This work was funded in part by a grant from the Emergency Medicine Foundation. None of the authors have financial or other interests in the medications used in this study. Address for correspondence and reprints: James R. Miner, MD; jimminer@hotmail.com. ISSN ª 2008 by the Society for Academic Emergency Medicine 1234 PII ISSN doi: /j x
2 ACAD EMERG MED December 2008, Vol. 15, No variety of available pain medications and routes of administration. Given the wide variety of situations that require the treatment of pain in the ED, it stands to reason that having a wide variety of treatment options available would be beneficial. However, despite the frequency with which various pain medications are used, the relative efficacy and safety of different treatment practices have only been compared in a few studies. 7 It is common practice to place an intravenous (IV) line and treat the patient in pain with titrated doses of opioid until adequate pain control has been achieved A common barrier to this approach is the timing of, and potential difficulty in, the placement of an IV line. A critically ill patient usually receives an IV very quickly; but those who are less ill and are hemodynamically stable may get the IV placed less quickly, especially during periods of overcrowding when available resources are limited. 8,9 Because of the unpredictable nature of the demand for resources in the ED, treatment approaches that do not require the time-consuming placement of an IV may be useful starting points for pain treatment in some situations. Intravenous morphine sulfate at weight-based doses of 0.1 mg kg is a common treatment for moderate to severe musculoskeletal pain, with few reported side effects. 10,11 IV morphine is titratable, allowing customized delivery for individual patients. Oral opioids are also used frequently in the treatment of pain in the ED, often in combination with acetaminophen (e.g., Percocet). The titration of oral opioids is difficult due to variability in the absorption of the drug. Oxycodone has primarily been studied in cancer-related pain. However, in a 1998 study of postoperative pain, the same doses of IV oxycodone and morphine were used by patients with a patient-controlled analgesia pump, suggesting that the two drugs are equipotent in this type of pain when given intravenously. 12 Oral oxycodone has a bioavailability of 60% to 87% in cancer patients Therefore, using a bioavailability quotient of 0.8, we estimated that mg kg oxycodone will provide similar pain relief to 0.1 mg kg IV morphine at the time it reaches its peak effect. The objective of our study was to compare the time to administration after the order was placed, the side effects, and the analgesic effect at sequential time points after medication administration of an oral treatment strategy using oxycodone, with an IV treatment strategy using morphine sulfate, for the initial treatment of musculoskeletal pain in ED patients. Our null hypothesis was that there is no difference in the time of administration, the onset of detectable analgesic effect after administration, or the magnitude of analgesic effect between an oral treatment strategy using oxycodone solution and an IV treatment strategy using morphine sulfate. METHODS Study Design This was a prospective randomized controlled clinical trial of patients receiving treatment for musculoskeletal pain between June 1, 2006, and December 31, The institutional review board of Hennepin County Medical Center approved the study. Patients provided prospective informed consent or assent prior to enrollment. Parents or guardians provided consent for the enrollment of children into the study. In addition, patients less than 18 years and greater than 6 years of age provided assent for study enrollment. Study Setting and Population This study was performed at Hennepin County Medical Center, an urban county hospital with approximately 99,000 ED patient visits per year. In our ED, it is the usual practice to treat patients with severe acute musculoskeletal pain with IV morphine (0.1 mg kg IV, followed by 0.05 mg kg IV q10 minutes as needed tolerated) for pain control as soon as possible. Patients 6 years and older who were going to receive IV morphine for the treatment of musculoskeletal pain at the time of study entry, but did not yet have an IV placed, were eligible for the study and approached for enrollment. Patients who had received a pain medication within 30 minutes prior to enrollment, with an allergy to morphine or oxycodone, who were pregnant or nursing, had a history of significant hepatic or renal disease, had ongoing obstructive airway disease, were in respiratory distress, or who were clinically intoxicated were excluded. Eligible patients and the guardians of eligible children were approached to provide informed consent. Children 6 years of age or older were approached for assent. Study Protocol Consenting patients were randomized to treatment with either 0.1 mg kg morphine sulfate IV or mg kg oxycodone orally in a 5 mg 5 ml suspension. For each eligible patient, the next in a series of sealed, consecutively numbered envelopes was opened, revealing the treatment group to which the subject was assigned. Treatment group assignments were determined using computerized random number generation and were sealed in the envelopes prior to the start of enrollment in the study. Subjects were placed on a pulse oximetry monitor prior to drug administration, and naloxone was available at the bedside. The study was discontinued and rescue medications given at the discretion of the treating physician if it was felt that the patient was having increasing pain or insufficient improvement of pain prior to 40 minutes after administration of the medication. These conditions were considered treatment failures. Complications were defined as vomiting, an oxygen saturation of <97% at any time, a decrease in systolic blood pressure >20%, or withdrawal from the study due to increasing pain. Prior to drug administration, all medications the patient had received in the prior 6 hours were recorded. The time from the placement of the medication order by the treating physician to the time of the administration of the medication was recorded by trained research assistants. Blood pressure, pulse oximetry, and pain measurements were recorded at 0, 10, 20, 30, and 40 minutes after initiation of the treatment. Pain was measured using a 100-mm visual analog scale (VAS) containing the words no pain on one end and the words worst pain possible on the other. Subjects
3 1236 Miner et al. IV VERSUS ORAL TREATMENT FOR ACUTE PAIN could not see their previous VAS scores. Physicians were blinded to the subjects VAS scores. After the 40- minute time point, the treating physician was asked whether or not the patient had received adequate pain relief from the treatment given, whether or not the patient would require further pain medications, and whether or not they intended to continue using the current route of administration of pain medication. Patients were asked to complete a 5-point scale describing their satisfaction with their pain treatment, with 1 being not satisfied and 5 being completely satisfied. VAS measurements were administered to the subjects and the treating physicians by trained research assistants, who collected all study data. Data Analysis Data were initially entered into an Excel (Microsoft Corp., Redmond, WA) spreadsheet and then exported into STATA 10.0 (StataCorp, College Station, TX) for analysis. Sample size calculations were performed using StudySize 2.0 (CreoStat HB, Sweden). Descriptive statistics were used as appropriate. The absolute and the percent change in VAS scores and the time to administration were compared between groups at each time point using Wilcoxon rank sum tests. The proportion of patients in each group who had a 50% decrease in their pain score was compared using chi-square tests. Changes in pain VAS scores between time points were compared using Wilcoxon sign rank tests. The proportion of patients in each group who were deemed to have adequate pain relief by their treating physician and the number of complications in the groups were compared using Fischer s exact test. We chose to use the percent change in VAS scores in addition to the absolute change in VAS scores to account for the possibility that analgesic effects may be different depending on the magnitude of a patient s pain and to avoid overestimating pain relief in patients with high initial scores and underestimating relief in patients with low initial scores. To detect a 10% difference in the change of VAS scores between groups with a power of 0.8 and a significance of 0.05 using a Wilcoxon rank sum test, 122 patients were needed in each group. RESULTS A total of 405 patients were identified during the study period; 328 (81.0%) patients consented to be in the study. A total of 158 patients were randomized to the IV morphine sulfate treatment group and 162 were randomized to the oral oxycodone treatment group. Of the patients who were randomized to IV therapy, 26 were withdrawn from the study prior to initiation, leaving 126 patients in the IV group for analysis. Of the patients who were randomized to oral therapy, 16 were withdrawn from the study prior to initiation (Figure 1). Summary baseline data is presented in Table 1. There were no significant differences between the groups. Table 2 contains the medications patients had received prior to study enrollment, from 6 hours before arrival in the ED and more than 30 minutes prior to study enrollment while in the ED. There was no difference between the two groups in the number of patients 320 patients enrolled Randomization 158 IV morphine 162 Oral oxycodone 26 withdrawn before start 16 withdrawn before start 8 protocol violations 6 protocol violations 7 = no IV possible 6 = age < 7 years 1 = age < 7 years 125 for analysis 140 for analysis Figure 1. Study timeline and enrollment. IV = intravenous. receiving pain medications prior to study enrollment (p = 0.53). No changes greater than 10% occurred in heart rate or blood pressure at any of the study time points. The median heart rate after medication administration was 75 for the IV therapy group (range, 49 to 126) and 77 beats min for the oral therapy group (range, 55 to 129 beats min). The median systolic blood pressure after medication administration was 116 mm Hg, (range, to mm Hg). Data regarding the pain relief achieved at each study time point are displayed in Figures 2 and 3 and compared in Tables 3 and 4. The VAS score and the percent change in the VAS score were different from baseline at each time point by Wilcoxon sign rank test (<0.001 for each test). There was a decrease in the VAS scores after treatment compared to baseline at all time points for the IV therapy group. There was not a statistically significant decrease in pain for patients in the oral therapy group until 30 minutes after treatment. At the 10- and 20-minute time points, the IV treatment group had a larger decrease in pain than the oral treatment group. By 30 minutes after treatment, both groups reported the same reduction of pain. The number of patients who achieved a 50% decrease in their pain scores was larger for patients in the IV therapy group than those in the oral therapy group at the 10- and 20-minute time points. However, at the 30- and 40-minute time points, we could no longer detect a difference in the number of patients in each group with at least a 50% reduction in pain (Table 5). Two patients had oxygen saturations <93% transiently prior to the 10-minute time point. Both patients were in the IV morphine group, and their oxygen saturations returned to >93% within 1 minute with no treatment. There were more treatment failures
4 ACAD EMERG MED December 2008, Vol. 15, No Table 1 Baseline Data IV Therapy Oral Therapy p-value Number Age (years), median (range) 36 (13 to 80) 40 (10 to 89) 0.92 Gender (% male) Weight (kg), (median; IQR), 73.2 (75; 59 to 84) 74.7 (75; 60 to 90) 0.35 Time to medication after enrollment (min), 20.5 (14 to 31; 2 to 124) 8.5 (5 to 15; 1 to 60) <0.001 median (IQR; range) Medication dose (mg kg), median, (IQR) 0.1 (0.08 to 0.10) (0.11 to 0.14) Pulse oximetry (%), median (IQR) 98 (97 to 99) 98 (97 to 99) 0.48 Baseline VAS, median (IQR) 85 (72 to 98) 86 (72.5 to 98) 0.87 IQR = interquartile range. Table 2 Medications Received before Study Enrollment Prestudy Treatment IV Morphine Sulfate, before ED Arrival,* n Rx, in ED, n Oral Oxycodone, before ED Arrival,* n Rx, in ED, n Acetaminophen NSAID Oral opioid Parenteral opioid ED = emergency department; IV = intravenous; NSAID = nonsteroidal anti-inflammatory drug; Rx = prescribed. *Up to 6 hours prior to ED arrival. Treated in the ED more than 30 minutes prior to study enrollment. VAS score (mm) VAS Scores By Time and Group % Decrease in VAS score Change in VAS from Baseline By Time and Group Time Point (min) Oral Therapy IV Therapy Time Point (min) Oral therapy IV therapy Figure 2. VAS scores by time and group. VAS = visual analog scale. (rescue pain medications were provided) at the 10- and 20-minute time points in the IV therapy group than in the oral therapy group (Table 6). No other adverse events, including vomiting, were detected. There was a 12-minute difference (p = 0.001, Wilcoxon rank sum) between the median time between the order and the administration of oral oxycodone (8.5 minutes) and IV morphine (20.5 minutes; Table 1). The satisfaction scale score was higher after treatment for the morphine group (median = 4; interquartile range [IQR] = 4 to 5) than for the oxycodone group (median = 4; IQR = 2 to 5; p = 0.008). Physicians considered the pain treatment adequate in (68.8%) of Figure 3. Change in VAS from baseline by time and group. VAS = visual analog score. patients in the IV group and in (54.3%) of the oral group (p = 0.03). There was no difference in the rate at which physicians felt that further medications were needed after the 40-minute time point ( [54.4%] vs [54.3%]; p = 0.96) or in the number who planned to continue to use the current route of administration to give the patient further doses of pain medicine ( [54.0%] vs [54.3%]; p = 0.96). DISCUSSION The IV administration of morphine is a common approach to the treatment of pain. This is usually
5 1238 Miner et al. IV VERSUS ORAL TREATMENT FOR ACUTE PAIN Table 3 Figure Summary: Change in VAS from Baseline IV therapy group )22.9 ()6.8, )46.8) )11.2 ()2.2, )39.4) )31.0 ()15.0, )71.0) )43.7 ()15.6, )79.7) Oral therapy group )7.5 (0, )23.5)% )3.1 ()7.6, )25.0) )37.4 ()9.7, )72.3) )32.6 ()6.1, )73.9) p-value (Wilcoxon rank sum) < Data are reported as median % (IQR). IQR = interquartile range; IV = intravenous; VAS = visual analog scale. Table 4 Figure Summary: VAS Scores IV therapy 64.5, (44 to 82) 74.5, (44 to 97) 55, (25 to 71) 47, (17 to 70) Oral therapy 75, (58 to 94) 80, (60 to 97) 49, (22 to 74) 56.5, (17.5 to 80.5) p-value (Wilcoxon rank sum) < Data are reported as median mm (IQR). IQR = interquartile range; IV = intravenous; VAS = visual analog scale. Table 5 50% Change in VAS Score* Oral therapy group (7.8) (4.5) (43.2) (37.7) IV therapy group (23.8) (22.0) (38.9) (44.4) p-value < IV = intravenous; VAS = visual analog scale. *n total at measured time (%). Table 6 Treatment Failures (Received a Rescue Medicine, Cumulative): IV Morphine Sulfate* IV therapy group (7.2) (9.6) (19.2) (19.2) Oral therapy group (2.8) (2.9) (19.3) (19.3) p-value *n total (%); cumulative over duration of the study. IV = intravenous. accomplished easily; however, technical difficulties and limited resources can sometimes delay the placement of an IV line. The goal of this study was to determine if an oral loading strategy could achieve similar pain relief to an IV one and to measure the delay to achieve pain relief when an oral strategy is used in place of an IV strategy. To determine this, we measured the effectiveness of two routes of administration of bioequivalent doses of two pain medications and found that IV morphine sulfate decreases pain significantly 10 minutes after administration, while oral oxycodone provides equivalent pain relief 30 minutes after administration. From the patient s perspective, however, the goal of ED management is the relief of pain as soon as possible, and the time to achieve any pain relief after arrival to the ED is the most relevant measure. While patients in the IV therapy group achieved pain relief earlier after treatment than those in the oral therapy group (i.e., larger decreases in VAS pain scores at 10 and 20 minutes), the time to administration of the medications was significantly shorter for those receiving oral oxycodone. When the time to significant pain relief is added to the time required for drug administration (10 minutes minutes for the IV therapy group and 30 minutes minutes for the oral therapy group), the time at which pain relief was detected once the order had been placed was similar for the two groups.
6 ACAD EMERG MED December 2008, Vol. 15, No There are many factors affecting the time it takes to administer an ordered pain medication in the ED, such as current work demands on nursing and patient overcrowding. 8 In addition, the delivery of IV medications is affected by the ability to start an IV on the patient needing pain relief. In our study, seven patients were withdrawn from the study due to difficulty placing an IV and, in our busy ED, oral medications were delivered much more quickly than IV pain medications. We found that, considering inherent delays in IV starts, patients receiving either oral or IV medication achieved relief at similar times after the treatments were ordered. Despite the small difference in the overall time to any pain relief after the treatment was ordered, patients in the IV therapy group were more satisfied with their pain treatment than those receiving in the oral therapy group. It is possible that placement of an IV suggests to the patients that the reported pain is being taken more seriously or that more care is actually being delivered when an IV is placed. In addition, physicians perceived greater pain relief in patients who had received IV medication. However, more patients in the morphine group received rescue medications than in the oral oxycodone group. It is possible that the fact that patients appeared more satisfied influenced the physician s perception of the patient s pain relief. These perceptions may represent a significant drawback to the use of oral oxycodone as a routine replacement for IV morphine. We used oxycodone without acetaminophen so it would be possible to give further doses of the medication. Unlike IV morphine, however, the timing and rate at which oral oxycodone can be titrated is not known. We can, however, conclude, that we did not detect a difference in the rate of adverse events (two hypoxic events for morphine vs. no events for oxycodone), that mg kg oxycodone appears to be a safe initial loading dose for management of pain for ED patients, and that it has an effect similar to that of 0.1 mg kg IV morphine 30 minutes after administration. LIMITATIONS This study was not blinded because our intention was to compare two different clinical strategies and the timing of the administration of the treatments. We could have blinded this study by having all patients receive IV drug or placebo and oral drug or placebo. Our intent, however, was to study the clinical approach to pain treatment, not the actual drugs, whose efficacy has been long established. We initially intended to study all patients, including children less than 7 years old. Patient-derived VAS scores have not been found to be accurate in children less than 7 years, and we therefore would need to use physician-derived pain scales. Due to the problems of using physician-derived pain scales in a nonblinded study where the physician controlled the determination of treatment failure, it was felt that this would yield data that was difficult to interpret and these patients were excluded from our study. For both medications, the doses that we studied here appeared to be too low to provide pain relief in the majority of patients. Our rate of treatment failure with this protocol was high. This has previously been observed for IV morphine given at these doses. 10,11 The doses of medication actually given to our study patients were lower than the doses the protocol called for in both the morphine and the oxycodone dose. Our protocol controlled the ordering of the medication but not the actual administration of the medicine. This is similar to previous findings in pain medication research that have noted that pain medications tend to be given in smaller doses than they are actually ordered. 17 In light of the fact that there were few adverse events other than treatment failures (i.e., the need for rescue medications), larger doses of both medications should be considered. CONCLUSIONS The oral loading strategy using oxycodone solution provided similar pain relief to the IV strategy using morphine sulfate 30 minutes after administration of the drugs. When considering the time to any pain relief (time to drug administration + time to pain relief), we found the oral treatment group and the IV treatment group to be similar. When the time to administration was not taken into account, patients receiving IV morphine reported faster pain relief, a greater degree of pain relief at an earlier time, and greater satisfaction with IV morphine than with oral oxycodone. Oral oxycodone represents a feasible alternative to IV morphine in the treatment of severe acute musculoskeletal pain when difficult or delayed IV placement (greater than 30 minutes) presents a barrier to treatment. References 1. Hostetler MA, Auinger P, Szilagyi PG. Parenteral analgesic and sedative use among ED patients in the United States: combined results from the National Hospital Ambulatory Medical Care Survey (NHAMCS) Am J Emerg Med. 2002; 20: Miner J, Biros MH, Trainor A, Hubbard D, Beltram M. Patient and physician perceptions as risk factors for oligoanalgesia: a prospective observational study of the relief of pain in the emergency department. Acad Emerg Med. 2006; 13: Rupp T, Delaney KA. Inadequate analgesia in emergency medicine. Ann Emerg Med. 2004; 43: Todd KH, Ducharme J, Choiniere M, et al. Pain in the emergency department: results of the pain and emergency medicine initiative (PEMI) multicenter study. J Pain. 2007; 8: Todd KH, Sloan EP, Chen C, Eder S, Wamstad K. Survey of pain etiology, management practices and patient satisfaction in two urban emergency departments. Can J Emerg Med. 2002; 4: Wilson JE, Pendleton JM. Oligoanalgesia in the emergency department. Am J Emerg Med. 1989; 7: Chang AK, Bijur PE, Meyer RH, Kenny MK, Solorzano C, Gallagher EJ. Safety and efficacy of hydromorphone as an analgesic alternative to
7 1240 Miner et al. IV VERSUS ORAL TREATMENT FOR ACUTE PAIN morphine in acute pain: a randomized clinical trial. Ann Emerg Med. 2006; 48: Pines JM, Hollander JE. Emergency department crowding is associated with poor care for patients with severe pain. Ann Emerg Med. 2008; 51: Miner JR, McClain C. Time to administration of pain medications as a marker for overcrowding [abstract]. Ann Emerg Med. 2006; 48(4 Suppl 1): Bijur PE, Kenny MK, Gallagher EJ. Intravenous morphine at 0.1 mg kg is not effective for controlling severe acute pain in the majority of patients. Ann Emerg Med. 2005; 46: Birnbaum A, Esses D, Bijur PE, Holden L, Gallagher EJ. Randomized double-blind placebo-controlled trial of two intravenous morphine dosages (0.10 mg kg and 0.15 mg kg) in emergency department patients with moderate to severe acute pain. Ann Emerg Med. 2007; 49: Silvasti M, Rosenberg P, Seppala T, Svartling N, Pitkanen M. Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient-controlled analgesia. Acta Anaesthesiol Scand. 1998; 42: Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther. 1990; 47: Kalso E, Vainio A, Mattila MJ, Rosenberg PH, Seppala T. Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. Pharmacol Toxicol. 1990; 67: Leow KP, Smith MT, Watt JA, Williams BE, Cramond T. Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. Ther Drug Monit. 1992; 14: Leow KP, Smith MT, Williams B, Cramond T. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther. 1992; 52: Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994; 330:592 6.
Safe IV Opioid Titration in Patients With Severe Acute Pain
PAIN CARE Safe IV Opioid Titration in Patients With Severe Acute Pain Chris Pasero, MS, RN-BC, FAAN PROVIDING EFFECTIVE PAIN control while minimizing opioid-induced adverse effects in patients with severe
More informationMorphiDex (MS:DM) Double-Blind, Multiple-Dose Studies In Chronic Pain Patients
Vol. 19 No. 1(Suppl.) January 2000 Journal of Pain and Symptom Management S37 Proceedings Supplement NMDA-Receptor Antagonists: Evolving Role in Analgesia MorphiDex (MS:DM) Double-Blind, Multiple-Dose
More informationEffective pain management begins with OFIRMEV (acetaminophen) injection FIRST Proven efficacy with rapid reduction in pain 1
Effective pain management begins with OFIRMEV (acetaminophen) injection FIRST Proven efficacy with rapid reduction in pain 1 Fast onset of pain relief with 7% reduction in visual analog scale (VAS) scores
More informationClinical Trial Results with OROS Ò Hydromorphone
Vol. 33 No. 2S February 2007 Journal of Pain and Symptom Management S25 Advances in the Long-Term Management of Chronic Pain: Recent Evidence with OROS Ò Hydromorphone, a Novel, Once-Daily, Long-Acting
More informationWarming Intravenous Fluids for Improved Patient Comfort in the Emergency Department: A Pilot Crossover Randomized Controlled Trial
Brief Research Report Warming Intravenous Fluids for Improved Patient Comfort in the Emergency Department: A Pilot Crossover Randomized Controlled Trial Wesley H. Self, MD, MPH Steven J. White, MD Candace
More information1 Emergency Medicine Academic Group, Department of Cardiovascular Sciences, University of Leicester, UK.
Title: A week of pain in the Emergency Department Authors: Thornton HS 1, Reynolds J 1, Coats TJ 1 1 Emergency Medicine Academic Group, Department of Cardiovascular Sciences, University of Leicester, UK.
More informationA randomised, double-blind, parallel group, multicentre study to compare the tolerability, safety, and efficacy of oxycodone with morphine in
A randomised, double-blind, parallel group, multicentre study to compare the tolerability, safety, and efficacy of oxycodone with morphine in patients using i.v. patient-controlled analgesia (PCA) for
More informationSatisfactory Analgesia Minimal Emesis in Day Surgeries. (SAME-Day study) A Randomized Control Trial Comparing Morphine and Hydromorphone
Satisfactory Analgesia Minimal Emesis in Day Surgeries (SAME-Day study) A Randomized Control Trial Comparing Morphine and Hydromorphone HARSHA SHANTHANNA ASSISTANT PROFESSOR ANESTHESIOLOGY MCMASTER UNIVERSITY
More informationClinical Trial Results Summary Study EN3409-BUP-305
Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Advil / Ibuprofen
More informationALVIMOPAN 0.0 OVERVIEW
ALVIMOPAN 0.0 OVERVIEW A. Alvimopan is a peripherally restricted mu-opioid receptor antagonist. B. DOSING INFORMATION : For the treatment of opioid bowel dysfunction, oral alvimopan doses between 0.5 milligrams
More informationFENTANYL BY CONSTANT RATE I.V. INFUSION FOR POSTOPERATIVE ANALGESIA
Br. J. Anaesth. (1985), 5, 250-254 FENTANYL BY CONSTANT RATE I.V. INFUSION FOR POSTOPERATIVE ANALGESIA W. S. NIMMO AND J. G. TODD is a synthetic opioid analgesic 50 times more potent than morphine, with
More informationPain Management after Major Orthopedic Surgery with the Sufentanil Sublingual Microtablet System
Pain Management after Major Orthopedic Surgery with the Sufentanil Sublingual Microtablet System David W. Griffin, MD Vero Beach, FL Disclosures/Acknowledgements Dr. Griffin received research funding and
More informationContinuing Medical Education Activity in Academic Emergency Medicine
CONTINUING MEDICAL EDUCATION Continuing Medical Education Activity in Academic Emergency Medicine CME Editor: Hal Thomas, MD Authors: Adrienne Birnbaum, MD, MS, Clyde Schechter, MD, MA, Virginia Tufaro,
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Vicodin CR Name of Active Ingredient: Page: Hydrocodone/Acetaminophen
More informationA Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled-Release
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled-Release Oxycodone/Acetaminophen Tablets (CR OC/APAP) in an Acute Pain Model Neil
More informationMORPHINE ADMINISTRATION
Introduction Individualised Administration Drug of Choice Route of Administration & Doses Monitoring of Neonates & high risk patients Team Management Responsibility Morphine Protocol Flow Chart Introduction
More informationOFIRMEV a non-opioid, non-nsaid, intravenous analgesic for the management of pain
FOR PHARMACY PROFESSIONALS In pharmacokinetic studies Rapid time to reach Cmax with IV acetaminophen OFIRMEV from the start OFIRMEV g demonstrated early and high Cmax at minutes Consider administering
More informationHOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain
Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid
More informationSupport for Acetaminophen 1000 mg Over-the-Counter Dose:
Support for Acetaminophen 1000 mg Over-the-Counter Dose: The Dental Impaction Pain Model and Efficacy and Safety Results from McNeil Randomized, Double-Blind, Single-Dose Study of Acetaminophen 1000 mg,
More informationMichigan General Procedures PAIN MANAGEMENT Date: November 15, 2012 Page 1 of 7
Date: November 15, 2012 Page 1 of 7 Pain Management The goal is to reduce the level of pain for patients in the pre-hospital setting. All non-cardiac pain should be assessed and scored according to the
More informationEfficacy and Safety of Sublingual Sufentanil 30 mcg for the Management of Acute Pain Following Ambulatory Surgery. Pamela P.
Efficacy and Safety of Sublingual Sufentanil 30 mcg for the Management of Acute Pain Following Ambulatory Surgery Pamela P. Palmer, MD, PhD Disclosures for Dr. Pamela Palmer AcelRx employee Currently own
More informationKetoprofen, diclofenac or ketorolac for pain after tonsillectomy in adults?
British Journal of Anaesthesia 82 (1): 56 60 (1999) Ketoprofen, diclofenac or ketorolac for pain after tonsillectomy in adults? P. Tarkkila* and L. Saarnivaara Department of Anaesthesia, Otolaryngological
More informationCLINICAL POLICY FOR THE USE OF INTRANASAL DIAMORPHINE FOR ANALGESIA IN CHILDREN ATTENDING THE PAEDIATRIC EMERGENCY DEPARTMENT, SASH
CLINICAL POLICY FOR THE USE OF INTRANASAL DIAMORPHINE FOR ANALGESIA IN CHILDREN ATTENDING THE PAEDIATRIC EMERGENCY DEPARTMENT, SASH Background Adequate analgesia is a vital aspect of early management of
More informationGUIDELINES AND AUDIT IMPLEMENTATION NETWORK
GUIDELINES AND AUDIT IMPLEMENTATION NETWORK General Palliative Care Guidelines The Management of Pain at the End Of Life November 2010 Aim To provide a user friendly, evidence based guide for the management
More informationProspective Validation of Clinically Important Changes in Pain Severity Measured on a Visual Analog Scale
ORIGINAL CONTRIBUTION Prospective Validation of Clinically Important Changes in Pain Severity Measured on a Visual Analog Scale From the Department of Emergency Medicine, Albert Einstein College of Medicine,
More informationA comparison of Ketoprofen and Diclofenac for acute musculoskeletal pain relief: a prospective randomised clinical trial
Hong Kong Journal of Emergency Medicine A comparison of Ketoprofen and Diclofenac for acute musculoskeletal pain relief: a prospective randomised clinical trial P Ng, CW Kam, HH Yau Objectives: To compare
More informationReducing the risk of patient harm: A focus on opioids
Reducing the risk of patient harm: A focus on opioids New York State Partnership for Patients (NYSPFP) Initiative Regional Educational Session November 2013 1 Disclosure Matthew Fricker, Matthew Grissinger,
More informationClinically Important Changes in Acute Pain Outcome Measures: A Validation Study
406 Journal of Pain and Symptom Management Vol. 25 No. 5 May 2003 Original Article Clinically Important Changes in Acute Pain Outcome Measures: A Validation Study John T. Farrar, MD, MSCE, Jesse A. Berlin,
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Transmucosal Fentanyl Effective Date... 4/15/2018 Next Review Date... 4/15/2019 Coverage Policy Number... 1018 Table of Contents Coverage Policy... 1 General
More informationA French, multicentre, placebo-controlled, randomised, double-blind,
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationNew Medicine Report (Adopted by the CCG until review and further
New Medicine Report (Adopted by the CCG until review and further DEXIBUPROFEN notice) Document Status Decision made at Suffolk D&TC 7 th September 2006 Traffic Light Decision Double Green Prescriber s
More informationIntravenous Dezocine for Postoperative Pain: A Double-Blind, Placebo-Controlled Comparison With Morphine
Intravenous for Postoperative Pain: A Double-Blind, Placebo-Controlled Comparison With Morphine Uma A. Pandit, MD, S aria P. Kothary, MD, and Sujit K. Pandit, MD, PhD, a new mixed agonist-antagonist opioid
More informationSingle- and Repeat-Dose Pharmacokinetics of Sublingual Sufentanil NanoTab in Healthy Volunteers
Single- and Repeat-Dose Pharmacokinetics of Sublingual Sufentanil NanoTab in Healthy Volunteers Pamela P. Palmer, MD, PhD AcelRx Pharmaceuticals, Inc. October 20, 2009 1 Sufentanil: A Superior Opioid Approved
More informationSupplementary Online Content
Supplementary Online Content Chang AK, Bijur PE, Esses D, Barnaby DP, Baer J. Effect of a single dose of oral opioid and nonopioid analgesics on acute extremity pain in the emergency department: a randomized
More informationDETERMINATION OF OXYCODONE CONTENT AND RELATED SUBSTANCES IN OXYCODONE AND ACETAMINOPHEN CAPSULE BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY
DETERMINATION OF OXYCODONE CONTENT AND RELATED SUBSTANCES IN OXYCODONE AND ACETAMINOPHEN CAPSULE BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY *Liandong Hu 1,2 and Yanjing Shi 1,2 1 School of Pharmaceutical
More informationPre-medication with controlled-release oxycodone in the management of postoperative pain after ambulatory laparoscopic gynaecological surgery
Page 1 of 5 Anaesthetics & Critical Care Pre-medication with controlled-release oxycodone in the management of postoperative pain after ambulatory laparoscopic gynaecological surgery B Lim 1, SY Thong
More informationRescue medications. What are rescue medications? Ideal rescue medication. Why use rescue medications?
Rescue medications Out-of-hospital treatment of prolonged seizures or acute repetitive seizures What are rescue medications? Medicines used to terminate a prolonged seizure or acute repetitive seizures
More informationRule Governing the Prescribing of Opioids for Pain
Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This
More informationHydrocodone/Acetaminophen Extended-Release Tablets M Clinical Study Report R&D/09/1109
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-712 Volume: Hydrocodone/Acetaminophen Extended-Release Name
More informationInternational Journal of Medical Toxicology and Forensic Medicine. 2012;2(2):56-60.
International Journal of Medical Toxicology and Forensic Medicine. 2012;2(2):56-60. Does Pethidine Hydrochloride Analgesia in Patients with Acute Appendicitis Alter the Diagnostic Accuracy of Clinical
More informationdiclofenac, 75mg/2ml of solution for intravenous injection (Dyloject ) No. (446/08) Javelin Pharmaceuticals UK Ltd
Scottish Medicines Consortium diclofenac, 75mg/2ml of solution for intravenous injection (Dyloject ) No. (446/08) Javelin Pharmaceuticals UK Ltd 11 February 2008 The Scottish Medicines Consortium has completed
More informationConversion to Oral Controlled-Release Oxycodone From Intravenous Opioid Analgesic in the Postoperative Setting
PA I N M E D I C I N E Volume 4 Number 1 2003 Conversion to Oral Controlled-Release Oxycodone From Intravenous Opioid Analgesic in the Postoperative Setting Brian Ginsberg, MB, BCh, a Raymond S. Sinatra,
More informationIndividuals with psychiatric illnesses represent a significant
CLINICAL INVESTIGATIONS Emergency Medicine and Psychiatry Agreement on Diagnosis and Disposition of Emergency Department Patients With Behavioral Emergencies Amy M. Douglass, John Luo, MD and Larry J.
More informationDate 8/95; Rev.12/97; 7/98; 2/99; 5/01, 3/03, 9/03; 5/04; 8/05; 3/07; 10/08; 10/09; 10/10 Manual of Administrative Policy Source Sedation Committee
Code No. 711 Section Subject Moderate Sedation (formerly termed Conscious Sedation ) Date 8/95; Rev.12/97; 7/98; 2/99; 5/01, 3/03, 9/03; 5/04; 8/05; 3/07; 10/08; Manual of Administrative Policy Source
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Tralieve 50 mg/ml solution for injection for dogs (AT, BE, BG, CY, CZ, DE, EL, ES, HR, HU, IE, IT, LU, NL, PT, RO,
More informationExternal Validation of the Clinical Dehydration Scale for Children With Acute Gastroenteritis
CLINICAL INVESTIGATION External Validation of the Clinical Dehydration Scale for Children With Acute Gastroenteritis Benoit Bailey, MD, MSc, Jocelyn Gravel, MD, MSc, Ran D. Goldman, MD, Jeremy N. Friedman,
More informationIndividual Study Table Referring to Part of the Dossier. Page:
2. SYNOPSIS Title of Study: A phase III comparative study of the pharmacokinetic/pharmacodynamic and safety profiles of extended release, regular release and placebo during a 12 hour observation in post-extraction
More informationEQUIPMENT: Nitrous Oxygen Delivery System:
Policy: Nitrous Oxide Use in the Intrapartum and Immediate Postpartum Period for Obstetrical Patients in the Family Birth Place Approvers: CEO. CNO, Medical Staff President, Anesthesia Chair, OB Medical
More informationnon-opioid versus oxycodone 2.7 ( 9.3to3.9);codeineversus oxycodone
Emergency Medicine Australasia (2016) 28,, 666 672 doi: doi: 10.1111/1742-6723.12672 ORIGINAL RESEARCH A randomised controlled trial of paracetamol and ibuprofen with or without codeine or oxycodone as
More informationIndividual Study Table Referring to Part of the Dossier. Page:
2. SYNOPSIS Title of Study: A comparative study of the pharmacokinetic/pharmacodynamic and safety profiles of extended release, regular release and placebo during a 12 hour observation in post-extraction
More informationS. Mitra (*), V. Ahuja (*), R. Kaushik (**)
(Acta Anaesth. Belg., 2017, 68, 199-204) Comparative study of analgesic efficacy and tolerability of oral tapentadol-paracetamol combination vs. oral tramadol-paracetamol combination for postoperative
More informationImmediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Hydrocodone Bitartrate- Acetaminophen (NORCO ) Name of
More informationSource of effectiveness data The evidence for the final outcomes and resource use were derived from a single study.
Gastroenterologist-administered propofol versus meperidine and midazolam for advanced upper endoscopy: a prospective, randomized trial Vargo J J, Zuccaro G, Dumot J A, Shermock K M, Morrow J B, Conwell
More informationType of intervention Anaesthesia. Economic study type Cost-effectiveness analysis.
Comparison of the costs and recovery profiles of three anesthetic techniques for ambulatory anorectal surgery Li S T, Coloma M, White P F, Watcha M F, Chiu J W, Li H, Huber P J Record Status This is a
More informationA Pharmacokinetic Study to Compare Two Simultaneous 400 µg Doses with a Single 800 µg Dose of Oral Transmucosal Fentanyl Citrate
Vol. 26 No. 2 August 2003 Journal of Pain and Symptom Management 743 Original Article A Pharmacokinetic Study to Compare Two Simultaneous 400 µg Doses with a Single 800 µg Dose of Oral Transmucosal Fentanyl
More informationDrug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA opioid analgesics) Avinza Butrans
FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics 7/9/2012 Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA
More informationStudy No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationResults of a one-year, retrospective medication use evaluation. Joseph Ladd, PharmD PGY-1 Pharmacy Resident BHSF Homestead Hospital
Results of a one-year, retrospective medication use evaluation Joseph Ladd, PharmD PGY-1 Pharmacy Resident BHSF Homestead Hospital Briefly review ketamine s history, mechanism of action, and unique properties
More informationThe Use of Controlled-Release Oxycodone for the Treatment of Chronic Cancer Pain: A Randomized, Double-Blind Study
Vol. 16 No. 4 October 1998 Journal of Pain and Symptom Management 205 Original Article The Use of Controlled-Release Oxycodone for the Treatment of Chronic Cancer Pain: A Randomized, Double-Blind Study
More informationE-Learning Module N: Pharmacological Review
E-Learning Module N: Pharmacological Review This Module requires the learner to have read Chapter 13 of the Fundamentals Program Guide and the other required readings associated with the topic. Revised:
More informationSafety and Effectiveness of Intravenous Morphine for Episodic Breakthrough Pain in Patients Receiving Transdermal Buprenorphine
Vol. 32 No. 2 August 2006 Journal of Pain and Symptom Management 175 Original Article Safety and Effectiveness of Intravenous Morphine for Episodic Breakthrough Pain in Patients Receiving Transdermal Buprenorphine
More informationEffect of Ketorolac on Pain Scores and Length of Stay in Post Anaesthetic Care Unit after Major Abdominal Surgery
Effect of Ketorolac on Pain Scores and Length of Stay in Post Anaesthetic Care Unit after Major Abdominal Surgery Amanat Khan, Ghulam Sabir Iqbal, Azra Naseem, Mohammad Usman Ahmed, Omer Salahuddin Department
More informationScottish Medicines Consortium
Scottish Medicines Consortium fentanyl 50 micrograms / dose, 100 micrograms/dose, 200 micrograms / dose nasal spray (Instanyl ) No. (579/09) Nycomed UK Ltd 09 October 2009 The Scottish Medicines Consortium
More informationPCA PRESCRIPTION is valid for a maximum of 4 days unless ceased earlier. Date: BINDING MARGIN - NO WRITING BINDING MARGIN - NO WRITING
Attach ADR Sticker THESE INSTRUCTIONS EXPLAIN WHEN TO MAKE A CLINICAL REVIEW OR RAPID RESPONSE CALL, YOUR LOCAL ESCALATION PROTOCOL WILL EXPLAIN HOW TO MAKE A CALL PCA ALLERGIES & ADVERSE DRUG REACTIONS
More informationWhat else is new (pain)? DR ANDREW DAVIES
What else is new (pain)? DR ANDREW DAVIES Introduction Outline Paracetamol for cancer pain IV paracetamol (for cancer pain) Vitamin D for cancer pain Paracetamol for cancer pain Paracetamol Mechanism of
More informationPo dilaudid versus iv dilaudid
Po dilaudid versus iv dilaudid Search IM/IV/SC 120 mg ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic an equianalgesic ratio for PO. Dilaudid official prescribing
More informationWhat s New in Post-Cesarean Analgesia?
Anesthesia & Obstetrics What s New in Post-Cesarean Analgesia? October 23rd, 2013 2013 UCSF What Does The Evidence Tell Us? Mark Rollins, MD, PhD UC SF Post-Delivery Pain (Mean pain scores for first 24
More informationJuly We hope that our tool will be a useful aid in your efforts to improve pain management in your setting. Sincerely, 7/14
July 2014 he Knowledge and Attitudes Survey Regarding Pain tool can be used to assess nurses and other professionals in your setting and as a pre and post test evaluation measure for educational programs.
More informationMEDICAL ADVISORY COUNCIL Position Statement PREHOSPITAL PAIN MANAGEMENT
MEDICAL ADVISORY COUNCIL Position Statement PREHOSPITAL PAIN MANAGEMENT MAC PS 2013-002 Appropriate treatment of acute pain in the prehospital arena offers an opportunity to positively impact many patients.
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationEquianalgesic Dosing: Making Opioid Interchange Easier. Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacist Assistant Professor Of Medicine
Equianalgesic Dosing: Making Opioid Interchange Easier Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacist Assistant Professor Of Medicine 1 Why Change Opioids? Side Effects Insufficient Pain
More informationOverview of Essentials of Pain Management. Updated 11/2016
0 Overview of Essentials of Pain Management Updated 11/2016 1 Overview of Essentials of Pain Management 1. Assess pain intensity on a 0 10 scale in which 0 = no pain at all and 10 = the worst pain imaginable.
More informationCanadian Expert Drug Advisory Committee Final Recommendation Plain Language Version
Canadian Expert Drug Advisory Committee Final Recommendation Plain Language Version BUPRENORPHINE TRANSDERMAL PATCH RESUBMISSION (BuTrans Purdue Pharma) Indication: Pain, Persistent (Moderate Intensity)
More informationLong Term Care Formulary HCD - 08
1 of 5 PREAMBLE Opioids are an important component of the pharmaceutical armamentarium for management of chronic pain. The superiority of analgesic effect of one narcotic over another is not generally
More informationProspective analysis of pain and pain management in an emergency department
Acta Biomed 2017; Vol. 88, Supplement 4: 19-30 DOI: 10.23750/abm.v88i4 -S.6790 Mattioli 1885 Original article Prospective analysis of pain and pain management in an emergency department Massimiliano Leigheb
More informationThe Participant will be able to: All Better!: Pediatric Adenotonsillectomy Pain Management
All Better!: Pediatric Adenotonsillectomy Pain Management Deborah Scalford, RN, MSN The Children s Hospital of Philadelphia Objectives The Participant will be able to: Identify reasons why pain is unrelieved.
More informationARTICLE. Oxycodone vs Placebo in Children With Undifferentiated Abdominal Pain
ARTICLE Oxycodone vs Placebo in Children With Undifferentiated Abdominal Pain A Randomized, Double-blind Clinical Trial of the Effect of Analgesia on Diagnostic Accuracy Hannu Kokki, MD; Hannu Lintula,
More informationFacilitating EndotracheaL Intubation by Laryngoscopy technique and Apneic Oxygenation Within the Intensive Care Unit (FELLOW)
Facilitating EndotracheaL Intubation by Laryngoscopy technique and Apneic Oxygenation Within the Intensive Data Analysis Plan: Apneic Oxygenation vs. No Apneic Oxygenation Background Critically ill patients
More informationDORIS DUKE MEDICAL STUDENTS JOURNAL Volume V,
Continuous Femoral Perineural Infusion (CFPI) Using Ropivacaine after Total Knee Arthroplasty and its Effect on Postoperative Pain and Early Functional Outcomes Eric Lloyd Scientific abstract Total Knee
More informationBuprenorphine Access in California
Buprenorphine Access in California James J. Gasper, PharmD, BCPP Pharmacy Benefits Division Department of Health Care Services james.gasper@dhcs.ca.gov Source: CDPH Vital Statisitics Death Statistical
More informationEarly Goal Directed Sedation In Critically Ill Patients
Early Goal Directed Sedation In Critically Ill Patients Yahya Shehabi, FCICM, FANZCA, EMBA Professor, Intensive Care Medicine Clinical School of Medicine, University New South Wales School of Epidemiology
More information6/6/2018. Nalbuphine: Analgesic with a Niche. Mellar P Davis MD FCCP FAAHPM. Summary of Advantages. Summary of Advantages
Nalbuphine: Analgesic with a Niche Mellar P Davis MD FCCP FAAHPM 1 Summary of Advantages Safe in renal failure- fecal excretion Analgesia equal to morphine with fewer side effects Reduced constipation
More informationNew Guidelines for Prescribing Opioids for Chronic Pain
New Guidelines for Prescribing Opioids for Chronic Pain Andrew Lowe, Pharm.D. CAPA Meeting October 6, 2016 THE EPIDEMIC Chronic Pain and Prescription Opioids 11% of Americans experience daily (chronic)
More informationReducing Adverse Drug Events: Strategies to Accelerate Improvement Webinar - Opioid Safety
This presenter has no conflicts of interest to disclose Reducing Adverse Drug Events: Strategies to Accelerate Improvement Webinar - Opioid Safety Frank Federico Vice President August 17, 2017 Objectives
More informationPharmacokinetics of strong opioids. Susan Addie Specialist palliative care pharmacist
Pharmacokinetics of strong opioids Susan Addie Specialist palliative care pharmacist What is the difference between pharmacokinetics and pharmacodynamics? Definitions Pharmacokinetics = what the body does
More informationPOST-OP PAIN MANAGEMENT
POST-OP PAIN MANAGEMENT You re Part of the Team Pain Management After Surgery Having a procedure or surgery to address a health issue can result in post-op (postoperative) pain. This pain can and should
More informationSupplementary Online Content
Supplementary Online Content Schmidt B, Whyte RK, Asztalos EV, et al; for the Canadian Oxygen Trial (COT) Group. Effects of targeting higher vs lower arterial oxygen saturations on death or disability
More informationCDC Guideline for Prescribing Opioids for Chronic Pain. Centers for Disease Control and Prevention National Center for Injury Prevention and Control
CDC Guideline for Prescribing Opioids for Chronic Pain Centers for Disease Control and Prevention National Center for Injury Prevention and Control THE EPIDEMIC Chronic Pain and Prescription Opioids 11%
More informationFunding: National Children s Research Centre, Ireland ISRCTN & EudraCT no
Severe Sickle Cell PaiN Intranasal Fentanyl (SSNIF) versus Intravenous Morphine - A Placebo-Controlled, Triple-Blind, Double-Dummy Non-Inferiority Randomized Controlled Trial Michael Joseph Barrett 1,2,3,
More informationYAKUGAKU ZASSHI 131(3) (2011) 2011 The Pharmaceutical Society of Japan
YAKUGAKU ZASSHI 131(3) 463 467 (2011) 2011 The Pharmaceutical Society of Japan 463 Regular Article Dose Conversion in Opioid Rotation from Continuous Intravenous Infusion of Morphine Hydrochloride Injection
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.259 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationExclusion Criteria 1. Operator or supervisor feels specific intra- procedural laryngoscopy device will be required.
FELLOW Study Data Analysis Plan Direct Laryngoscopy vs Video Laryngoscopy Background Respiratory failure requiring endotracheal intubation occurs in as many as 40% of critically ill patients. Procedural
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationARTICLE. Intravenous Ketorolac in the Emergency Department Management of Sickle Cell Pain and Predictors of Its Effectiveness
ARTICLE Intravenous Ketorolac in the Emergency Department Management of Sickle Cell Pain and Predictors of Its Effectiveness James L. Beiter, Jr, MD; Harold K. Simon, MD; C. Robert Chambliss, MD; Thomas
More informationPARACOD Tablets (Paracetamol + Codeine phosphate)
Published on: 22 Sep 2014 PARACOD Tablets (Paracetamol + Codeine phosphate) Composition PARACOD Tablets Each effervescent tablet contains: Paracetamol IP...650 mg Codeine Phosphate IP... 30 mg Dosage Form/s
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSubstitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
More informationAdult Policy for Strong Opioid Dosing (Acute Pain) Intermittent Oral and Subcutaneous Management
Adult Policy for Strong Opioid Dosing (Acute Pain) Intermittent Oral and Subcutaneous Management Contents Policy/Purpose... 1 Scope... 1 Associated documents... 1 Requirements for prescribing/administering
More information